医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

IDC MarketScape Report Names Mach7 a Leader in U.S. Healthcare Provider VNA/AICA Unstructured Data Platforms for Integrated Care

2016年06月07日 PM09:00
このエントリーをはてなブックマークに追加


 

BURLINGTON, Vt.

Mach7 Technologies (ASX:M7T), a global provider of enterprise imaging solutions, today announced it has been named a Leader in the IDC MarketScape: U.S. Healthcare Provider VNA/AICA Unstructured Data Platforms for Integrated Care 2016 Vendor Assessment (doc # US41287215, May 2016).

This study focuses on Vendor Neutral and Application-Independent Clinical Archive (VNA and AICA) platforms that allow providers to manage and provide access to disparate types of unstructured content among multiple departments, across the entire integrated delivery network (IDN), and between affiliated providers in the community.

Study Highlights Participants, Contenders, Major Players and Leaders

Using detailed surveys and interviews with end-users, vendors, and a review board of IDC experts, an accurate and consistent assessment of each vendor’s characteristics, behavior, and capability was created. Based on the review board’s findings, vendors were characterized as industry Participants, Contenders, Major Players or Leaders. Judy Hanover, a research director at IDC Health Insights and author of the report stated “This report, which identifies Mach7 Technologies as a Leader in the VNA and AICA Platform space, focused on many variables including functionality and patient-centricity of the product, underlying technology, market knowledge and reach of the vendor, deployment capabilities, value relative to price, and customer references for the product.”

“The next generation of VNA technologies, AICA, has evolved as a strategy to support U.S. healthcare organizations moving to integrated care,” Hanover elaborated. “AICA supports the needs of existing VNA users and systems while offering healthcare providers additional capabilities to address the challenges posed by the exponential growth of unstructured healthcare data and the deepening need for population health management (PHM) and the patient-centered medical home (PCMH) in new business models.”

“We think about enterprise imaging differently and we’re bold in our approach”, said Mach7 CTO Eric Rice. “Our culture of innovation and customer collaboration drives everything that we do. We listen to our customers and create the solutions that solve their business, collaboration and interoperability challenges clearing the way for improved patient care.”

About IDC MarketScape:
IDC MarketScape vendor analysis model is designed to provide an overview of the competitive fitness of ICT (information and communications technology) suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360 degree assessment of the strengths and weaknesses of current and prospective vendors.

About Mach7 Technologies
Mach7 Technologies (ASX:M7T) develops innovative enterprise imaging IT solutions that create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. Mach7’s award-winning enterprise imaging platform provides a vendor neutral foundation for unstructured data consolidation and communication to power interoperability and enables healthcare enterprises to build their best-of-breed clinical ecosystems. Mach7’s sophisticated workflow tools, advanced clinical viewing and optimized vendor neutral archiving solutions unlock silos of legacy systems empowering healthcare providers to own, access and share patient data without boundaries. Visit www.mach7t.com. Follow us on TwitterGoogle+Facebook, and LinkedIn.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160607005592/en/

CONTACT

Mach7 Technologies
Julia Vaughn, 802-768-0143
julia.vaughn@mach7t.com

同じカテゴリーの記事 

  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Apollo Hospital in New Delhi Initiates First Non-Invasive ZAP-X Brain Tumor Treatment in South Asia
  • ヒストソニックス、英国の新しいイノベーションプログラムIDAPに参加
  • HistoSonics成功加入英国新创新计划
  • HistoSonics Awarded Key Position in UK’s Novel Innovation Program